- Conditions
- Advanced Cancer
- Interventions
- MGCD265
- Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2019
- U.S. locations
- 12
- States / cities
- Duarte, California • Orange, California • San Diego, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 11,405
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Zanubrutinib, Ibrutinib
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 652 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 30
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Boulder, Colorado + 25 more
- Conditions
- Secondary Amenorrhea
- Interventions
- PROMETRIUM® 300 mg, PROMETRIUM® 400 mg
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 42
- States / cities
- Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 36 more
- Conditions
- Alcohol Risk Behaviors, Health Care Services Quality of Care
- Interventions
- Check Yourself App with Feedback
- Behavioral
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 13 Years to 18 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Seattle, Washington
- Conditions
- HIV-1
- Interventions
- F/TAF, 3rd ARV agent, Boosted PIs
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • Philadelphia, Pennsylvania + 1 more
- Conditions
- Ovarian Cancer
- Interventions
- Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
- Genetic · Combination Product
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Duarte, California • Augusta, Georgia + 6 more
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Tibial Fractures
- Interventions
- reamed, interlocking intramedullary nail, locking periarticular plate
- Device
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Davis, California • San Francisco, California + 22 more
- Conditions
- Recurrent Pericarditis
- Interventions
- VTX2735
- Drug
- Lead sponsor
- Zomagen Biosciences Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- La Jolla, California • Orange, California • Saint Augustine, Florida + 10 more
- Conditions
- Major Depression
- Interventions
- Psilocybin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more
- Conditions
- Chronic Myelogenous Leukemia - Chronic Phase
- Interventions
- asciminib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 80
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 71 more
- Conditions
- Caregiver, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer
- Interventions
- Telephone-Based Intervention, Caregiver-Assisted Training, Questionnaire Administration, Quality-of-Life Assessment
- Behavioral · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- Not listed
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Appendicitis
- Interventions
- Baseline, 30 Day Follow Up
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 17
- States / cities
- Baldwin Park, California • Los Angeles, California • Riverside, California + 11 more
- Conditions
- Parkinson Disease
- Interventions
- BIA 28-6156
- Drug
- Lead sponsor
- Bial R&D Investments, S.A.
- Industry
- Eligibility
- Not listed
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 13 more
- Conditions
- Breast Cancer
- Interventions
- metformin hydrochloride, placebo
- Drug · Other
- Lead sponsor
- Canadian Cancer Trials Group
- Network
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 3,649 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2023
- U.S. locations
- 280
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Scottsdale, Arizona + 213 more
- Conditions
- Node Positive HER2 Negative Breast Cancer
- Interventions
- Placebo, Aspirin
- Other · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 3,021 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1426
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 902 more
- Conditions
- Psoriatic Arthritis, Overweight or Obesity
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 53
- States / cities
- Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more
- Conditions
- Advanced Refractory Left Ventricular Heart Failure
- Interventions
- HeartMate 3 LVAS, HeartMate II LVAS
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 1,028 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 69
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • La Jolla, California + 53 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Not listed
- Lead sponsor
- Tempus AI
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 31
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 25 more
- Conditions
- Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
- Interventions
- TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Albumin-Bound Paclitaxel
- Drug
- Lead sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 18
- States / cities
- Gilbert, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more
- Conditions
- Moderate to High-risk Noncardiac Surgery
- Interventions
- Acumen HPI Smart Alerts and Smart Trends Software, The HemoSphere advanced monitoring platform with Acumen HPI software, and Acumen IQ sensor and Acumen IQ cuff
- Device
- Lead sponsor
- Becton, Dickinson and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 8
- States / cities
- Sacramento, California • Ann Arbor, Michigan • Detroit, Michigan + 5 more
- Conditions
- HIV Infections
- Interventions
- Ritonavir, AMD070
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2006
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Seattle, Washington
- Conditions
- Vulvovaginal Atrophy
- Interventions
- WC3011 Estradiol Vaginal Cream, Vehicle
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 48 more
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blastic Phase, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Disease
- Interventions
- Cyclosporine, Dasatinib, Fludarabine Phosphate, Imatinib Mesylate, Mycophenolate Mofetil, Nilotinib, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Therapeutic Allogeneic Lymphocytes, Total-Body Irradiation
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2018
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Seattle, Washington